Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Aviva's Q1 premiums up 9% as insurer gives bullish outlook

(Sharecast News) - Insurer Aviva said it was confident in achieving its group targets after a "great start" to 2025, with premiums rising by almost a tenth. Chief executive Amanda Blanc said the company is "very positive" about the full-year outlook and meeting its financial guidance.

"Our balance sheet is strong, we have a clear customer-focused strategy which we continue to deliver at pace and our market-leading businesses are growing well, especially in capital-light areas," she said.

General insurance premiums totalled £2.9bn in the three months to 31 March, up 9% on the year before, with strong performances in both personal and commercial insurance, including a travel insurance partnership with Nationwide and the benefits of acquiring Lloyd's insurer Probitas.

In the Wealth division, Aviva secured £2.3bn of net flows which is 5% of opening assets under management. Meanwhile, Retirement sales were 4% higher than last year at £1.8bn, as higher interest rates drove growth in individual annuities where sales increased by 32%. Protection and health insurance sales also jumped 19% to £126m.

In other news, Aviva said its takeover of Direct Line is "firmly on track". Despite Wednesday's news that competition regulators were investigating the £3.7bn deal, Blanc said that the acquisition should still complete by the middle of the year.

Sage said it was confident in meeting the medium-term projections set out in its 2023 results, targeting £2bn in operating profits by 2026, £1.8bn in Solvency II operating own funds generation, and cash remittances of more than £5.8bn cumulatively between 2024 and 2026.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.